<li id="quy4e"></li>
<button id="quy4e"></button>
  • <button id="quy4e"><bdo id="quy4e"></bdo></button>
    <rt id="quy4e"></rt>
    <tfoot id="quy4e"></tfoot>
  • 咨詢熱線

    15000266580

    當(dāng)前位置:首頁(yè) >產(chǎn)品中心>細(xì)胞庫(kù)>人腫瘤細(xì)胞、癌細(xì)胞>U-937人組織細(xì)胞淋巴瘤細(xì)胞

    人組織細(xì)胞淋巴瘤細(xì)胞

    簡(jiǎn)要描述:CRL-1593.2 U-937 人組織細(xì)胞淋巴瘤細(xì)胞,
    原代細(xì)胞|細(xì)胞系|細(xì)胞株|菌種;
    細(xì)胞庫(kù)管理規(guī)范,提供的細(xì)胞株背景清楚,
    提供參考文獻(xiàn)和培養(yǎng)條件!

    • 產(chǎn)品型號(hào):U-937
    • 廠商性質(zhì):生產(chǎn)廠家
    • 更新時(shí)間:2025-04-30
    • 訪  問  量:2146

    產(chǎn)品分類

    Product Category

    詳細(xì)介紹

    CRL-1593.2 U-937 人組織細(xì)胞淋巴瘤細(xì)胞

    ATCC® Number: CRL-1593.2™ Price:

    Designations: U-937

    Depositors: H Koren

    Biosafety Level: 1

    Shipped: frozen

    Medium & Serum: See Propagation

    Growth Properties: suspension

    Organism: Homo sapiens (human)

    Morphology: monocyte

    CRL-1593.2 U-937 人組織細(xì)胞淋巴瘤細(xì)胞

    Source: Disease: histiocytic lymphoma

    Cellular Products: lysozyme; beta-2-microglobulin (beta 2 microglobulin); tumor necrosis factor (TNF), also known as tumor necrosis factor alpha (TNF-alpha, TNF alpha), after stimulation with phorbol myristic acid (PMA)

    Permits/Forms: In addition to the MTA mentioned above, other ATCC and/or regulatory permits may be required for the transfer of this ATCC material. Anyone purchasing ATCC material is ultimay responsible for obtaining the permits. Please click here for information regarding the specific requirements for shipment to your location.


    Restrictions: The original U-937 cell line was established by Dr. K. Nilsson's laboratory in 1974 and he has requested the following: (1) In all papers reporting any use of this cell line or any derivatives thereof a direct reference should be made to Sundstrom and Nilsson (Int. J. Cancer 17: 565-577, 1976). (2) Any proposed commercial use of the cells should be negotiated with Professor Kenneth Nilsson, Rudbeck Laboratory, SE-751 85 Uppsala, Sweden. (3) No distribution of any of the cells or sublines derived therefrom should be made to third parties; (4) The cells should be used for non-clinical, non-commercial research only.

    Isolation: Isolation date: 1974

    Applications: transfection host (Roche FuGENE® Transfection Reagents

    Nucleofection technology from Lonza)

    Receptors: complement (C3)

    DNA Profile (STR): Amelogenin: X

    CSF1PO: 12

    D13S317: 10,12

    D16S539: 12

    D5S818: 12

    D7S820: 9,11

    THO1: 9.3

    TPOX: 8,11

    vWA: 15

    Age: 37 years

    Gender: male

    Ethnicity: Caucasian

    Comments: The U-937 cell line was derived by Sundstrom and Nilsson in 1974 from malignant cells obtained from the pleural effusion of a patient with histiocytic lymphoma.

    Studies since 1979 have shown that U-937 cells can be induced to terminal monocytic differentiation by supernatants from human mixed lymphocyte cultures,

    phorbol esters, vitamin D3, gamma interferon, tumor necrosis factor (TNF) and, retinoic acid.

    The cells are negative for immunoglobulin production and Epstein-Barr virus expression.

    The cells express the Fas antigen, and are sensitive to TNF and anti-Fas antibodies.

    In 1994, PCR and cytogenetic analyses showed that a number of stocks of U-937 were contaminated with the human myeloid leukemia cell line, K-562.

    In the earliest stocks available, the level of contamination was 0.6%. [40484]

    Distribution was discontinued in March 1994, except if required for patent purposes.

    Anyone who wishes to receive a sample of this original material should contact the Head of the ATCC Patent Depository.

    A stock of CRL-1593 found to be free of K-562 was propagated continuously for 8 weeks and tested weekly by PCR.

    Distribution and seed stocks give DNA profiles characteristic of U-937 only.

    Such preparations are now offered as authentic U-937 (ATCC CRL-1593.2) and are believed to be free of second subpopulations.

    Propagation: ATCC complete growth medium: The base medium for this cell line is ATCC-formulated RPMI-1640 Medium, Catalog No. 30-2001. To make the complete growth medium, add the following components to the base medium: fetal bovine serum to a final concentration of 10%.

    Atmosphere: air, 95%; carbon dioxide (CO2), 5%

    Temperature: 37.0°C

    Subculturing: Protocol: Cultures can be maintained by the addition of fresh medium or replacement of medium. Alternatively, cultures can be established by centrifugation with subsequent resuspension at 1 to 2 X 10(5) viable cells/ml.

    Interval: Maintain cell density between 1 X 10(5) and 2 X 10(6) viable cells/ml.

    Medium Renewal: Add fresh medium every 3 to 4 days (depending on cell density)

    Preservation: Freeze medium: Complete growth medium supplemented with 5% (v/v) DMSO

    Storage temperature: liquid nitrogen vapor phase

    Related Products: Recommended medium (without the additional supplements or serum described under ATCC Medium):ATCC 30-2001

    recommended serum:ATCC 30-2020

    References: 1080: Ralph P, et al. Lysozyme synthesis by established human and murine histiocytic lymphoma cell lines. J. Exp. Med. 143: 1528-1533, 1976. PubMed: 1083890

    21866: . Gene expression during normal and malignant differentiation. London: Academic Press; 1985.

    21876: . International symposium on new trends in human immunology and cancer immunotherapy. Paris: Doin Editeurs; 1980.

    22906: Koren HS, et al. In vitro activation of a human macrophage-like cell line. Nature 279: 328-331, 1979. PubMed: 450085

    22912: Gidlund M, et al. Natural killer cells kill tumour cells at a given stage of differentiation. Nature 292: 848-850, 1981. PubMed: 7266653

    23049: Olsson I, et al. Induction of differentiation of the human histiocytic lymphoma cell line U-937 by 1 alpha,25-dihydroxycholecalciferol. Cancer Res. 43: 5862-5867, 1983. PubMed: 6315218

    23103: Morimoto H, et al. Overcoming tumor necrosis factor and drug resistance of human tumor cell lines by combination treatment with anti-Fas antibody and drugs or toxins. Cancer Res. 53: 2591-2596, 1993. PubMed: 7684321




    CRL-1593.2 U-937




















    產(chǎn)品咨詢

    留言框

    • 產(chǎn)品:

    • 您的單位:

    • 您的姓名:

    • 聯(lián)系電話:

    • 常用郵箱:

    • 省份:

    • 詳細(xì)地址:

    • 補(bǔ)充說明:

    • 驗(yàn)證碼:

      請(qǐng)輸入計(jì)算結(jié)果(填寫阿拉伯?dāng)?shù)字),如:三加四=7
    聯(lián)系方式

    郵箱:xiangfbio@163.com

    地址:上海市虹口區(qū)四平路710號(hào)7層

    咨詢熱線

    400-821-8510

    (周一至周日9:00- 19:00)

    在線咨詢
    • 掃一掃 微信咨詢

    Copyright©2025 上海復(fù)祥生物科技有限公司 All Right Reserved    備案號(hào):滬ICP備10013034號(hào)-2     sitemap.xml
    技術(shù)支持:化工儀器網(wǎng)    管理登陸
    主站蜘蛛池模板: 金坛市| 营口市| 科尔| 博罗县| 玉山县| 灵石县| 竹山县| 札达县| 五河县| 六枝特区| 宝应县| 洪雅县| 丁青县| 原平市| 南涧| 满洲里市| 宁波市| 镶黄旗| 苗栗县| 门源| 弥勒县| 旌德县| 安福县| 岱山县| 安平县| 古交市| 和平县| 玉环县| 当雄县| 淳安县| 探索| 仁寿县| 淮安市| 甘肃省| 镇赉县| 天等县| 水城县| 宜川县| 花莲市| 寻甸| 迁西县|